Werewolf Therapeutics, Inc. (HOWL): Cash & Equivalents
$57.05M
As of 2025-12-31
$21.99M
As of 2026-06-30
-23.9%
3-year compound annual growth
-9.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.05M | -48.6% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $111.00M | -17.4% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $134.34M | +3.9% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $129.31M | -17.9% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $157.53M | +70.2% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $92.57M | n/a | 2022-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $57.05M | -48.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $66.00M | -30.1% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $4.58M | -47.6% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $70.04M | +28.5% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $16.98M | -23.3% |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $67.71M | +350.2% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $44.27M | -32.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
Compare HOWL, SPRO, CNTX, CRVS side by side · Screen every company in Pharmaceutical Preparations ↗